



UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: December 16, 2021

Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:02 PM		
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from September 9, 2021	Minutes reviewed, approved	Yes
A. Introduction - P&T Committee Updates	J. Hancovsky	Review of Medication Therapy Management (MTM): Reviewed program as a follow-up from the September P&T meeting where there was an ask from our committee member to provide a high-level overview regarding high medication utilizers.	Non voting item	Yes
B. Formulary Review - New Drugs	M. Reisman	Lumakras		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	M. Reisman	Empaveli		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	C. Lichtinger	Truseltiq		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	M. Reisman	Myfembree		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	M. Reisman	Verkazia		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - New Drugs (cont.)	C. Lichtinger	Wegovy		
		Recommendation: • Benefit exclusion across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	C. Lichtinger	Brexafemme		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	Comment:	• Dr. Kirk posed a question to the audience to see if providers anticipated using Brexafemme on a regular basis.		
	C. Lichtinger	Rezurock		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
	M. Reisman	Kerendia		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
B. Formulary Review - Class Reviews	C. Lichtinger	Long-Acting Insulin Analogs		
		Confirm class review	Yes/No	Yes
		Recommendation: • Insulin Glargine-yfgn : Preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review- New Formulations	M. Reisman	Confirm Review of New Formulations Grid	Yes/No	Yes
		Recommendation: • Myrbetriq Granules : Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - PDL Modifications	M. Reisman	Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Pravastatin : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Olmesartan : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Celecoxib : Remove prior authorization (PA) requirement, preferred without PA	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Ezetimibe : Remove prior authorization (PA) requirement, preferred without PA	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Long acting injectable antipsychotics (Abilify Maintena, Aristada, Invega Sustenna, Perseris, Risperdal Consta) : Move to preferred with Dx2Rx (diagnosis check) across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - New Drugs- Medical	M. Reisman	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Rybrevant		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Rylaze		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Saphnelo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
B. Formulary Review - Drugs Evaluated Per Grid	M. Reisman	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	9:0

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
C. Clinical Guidelines	M. Reisman	Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	9:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	9:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	9:0
D. Annual PDL Ratification	G. Shutzberg	Approve Preferred Drug Lists (PDLs) for each market, including the Wrap Plan File	Motion made, seconded, and carried to accept recommendation	9:0
E. Quality Monitoring	S. Kulik/C.Lichtinger	Confirm Review of Quality Data	Yes/No	Yes
	S. Kulik	DUR Review		
	Comment:	• Dr. Kirk posed a question to the audience if they received any adherence program faxes and if they found them helpful. There were no comments to that question.		
	C. Lichtinger	Top 25 Drugs by Cost and Volume – 3rd Quarter 2021		
	C. Lichtinger	Top 10 Drugs Requested - Approvals and Denials – 3rd Quarter 2021		
	C. Lichtinger	Grievances and Appeals Data – 3rd Quarter 2021		
	C. Lichtinger	Inter-Rater Reliability (IRR) – 3rd Quarter 2021 • Pharmacists • Medical Director (4th Quarter 2021)		
Adjournment	G. Shutzberg		6:35 PM	

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer, UHC C&S